Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Night Driving After Trifocal Versus Monofocal IOL Implantation (TriIOL)

5 août 2026 mis à jour par: Jin Yang

Night-Driving Visual Quality and Visual Disturbances After Bilateral Trifocal Versus Monofocal Intraocular Lens Implantation: A Prospective Observational Cohort Study

This prospective observational cohort study will compare night-driving visual difficulty and visual disturbances after bilateral implantation of an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens in adults undergoing cataract surgery. The type of intraocular lens will be selected by each participant and the treating ophthalmologist as part of routine clinical care, and will not be assigned by the investigators.

Eligible participants must have a valid motor vehicle driving license and a stable history of night driving during the previous 3 months. The primary outcome will be the total score of the Visual Function and Night Driving Questionnaire (VND-Q) at 3 months postoperatively. Secondary assessments will include glare adaptation, self-rated night-driving quality and driving speed, changes in night-driving behavior, visual disturbances, distance, intermediate and near visual acuity, contrast sensitivity, whole-eye aberrations, pupil diameter, defocus performance, reading speed, spectacle independence, and participant satisfaction.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Observationnel

Inscription (Estimé)

200

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Xuanqiao Lin, Doctor
  • Numéro de téléphone: +8615088920668
  • E-mail: 1532483480@qq.com

Lieux d'étude

  • Chine
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200000
        • Eye and ENT Hospital of Fudan University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adults aged 18 to 85 years with bilateral cataract who are scheduled to undergo bilateral phacoemulsification and in-the-bag implantation of either the same model of Alcon trifocal intraocular lens in both eyes or the same model of Alcon monofocal intraocular lens in both eyes. Participants must have a valid driving license and a stable history of night driving during the 3 months before enrollment.

La description

Inclusion Criteria:

  • Adults aged 18 to 85 years.
  • Scheduled to undergo bilateral phacoemulsification with in-the-bag intraocular lens implantation.
  • Both eyes scheduled to receive the same type and model of either an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens.
  • Possession of a valid motor vehicle driving license.
  • Stable night-driving behavior during the previous 3 months, with night driving occurring at least twice per month.
  • Lens Opacities Classification System III nuclear opalescence grade of 4 or lower in both eyes.
  • Expected intraocular lens power between +10.0 D and +36.0 D, inclusive, in both eyes.
  • Ability to understand the purpose and procedures of the study and independently complete the VND-Q and visual quality questionnaires.
  • Willingness to provide written informed consent and complete the scheduled postoperative follow-up visits.

Exclusion Criteria:

  • Corneal endothelial cell density below 1,500 cells/mm² in either eye.
  • History of ocular trauma affecting visual function, previous intraocular surgery, or previous corneal refractive surgery in either eye.
  • Strabismus, amblyopia, or nystagmus in either eye.
  • Any ocular disease that may affect postoperative visual acuity, contrast sensitivity, mesopic visual function, or questionnaire assessment, including but not limited to irregular corneal astigmatism, corneal scar, corneal degeneration, keratoconus, keratitis, corneal dystrophy, uveitis, severe iris atrophy, intraoperative floppy iris syndrome, microphthalmos, macrophthalmos, color vision deficiency, active ocular inflammation, advanced glaucoma or uncontrolled intraocular pressure, macular disease, retinal pigment epithelial disease, diabetic retinopathy, retinal detachment, choroidal detachment, or optic atrophy.
  • A high risk of zonular rupture or an contraindication to in-the-bag intraocular lens implantation, including zonular weakness, zonular dialysis, lens subluxation or dislocation, pseudoexfoliation syndrome, Marfan syndrome, posterior capsule rupture, or cyclodialysis.

Severe or unstable systemic disease, including systemic lupus erythematosus or Sjögren syndrome.

  • Use of medication judged by the investigator to increase surgical risk or affect visual function, including amiodarone, chlorpromazine, ethambutol, digitalis, or chloroquine.
  • Requirement for a combined ocular procedure, including limbal relaxing incisions, intraocular drug injection, retinal laser treatment, or another combined procedure judged inappropriate by the investigator.
  • Severe anxiety, depression, or another significant psychiatric disorder.
  • Any other condition judged by the investigator to make participation inappropriate.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Trifocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon trifocal intraocular lens in both eyes
Dispositif: AcrySof IQ PanOptix TFNT00 Trifocal Intraocular Lens
AcrySof IQ PanOptix TFNT00 Trifocal Intraocular Lens
Monofocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon monofocal intraocular lens in both eyes
Dispositif: Alcon Monofocal Intraocular Lens
Alcon Monofocal Intraocular Lens

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
VND-Q Total Score at 3 Months After Surgery
Délai: 3 months after the second-eye surgery
The Visual Function and Night Driving Questionnaire (VND-Q) consists of 9 items. Each item is rated on a 5-point Likert scale from 1, indicating no difficulty, to 5, indicating extreme difficulty. The total score ranges from 9 to 45, with higher scores indicating greater subjective difficulty during night driving.
3 months after the second-eye surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Glare Adaptation Item Score of the VND-Q
Délai: 3 months after the second-eye surgery
Score of the VND-Q item assessing difficulty adapting to glare from oncoming vehicle headlights. A higher score indicates greater difficulty with glare adaptation.
3 months after the second-eye surgery
Self-Rated Night-Driving Quality
Délai: Baseline and 3 months after the second-eye surgery
Participant-reported night-driving quality assessed using a study-specific 5-point rating scale. Higher or lower scores will be interpreted according to the predefined questionnaire scoring system.
Baseline and 3 months after the second-eye surgery
Self-Rated Night-Driving Speed
Délai: Baseline and 3 months after the second-eye surgery
Participant-reported assessment of usual night-driving speed using a study-specific 5-point rating scale.
Baseline and 3 months after the second-eye surgery
Percentage of Participants Who Reduce Night Driving
Délai: 3 months after the second-eye surgery
The number and percentage of participants reporting that they reduced their night-driving frequency after surgery, based on a binary yes-or-no questionnaire item.
3 months after the second-eye surgery
Distance, Intermediate, and Near Visual Acuity
Délai: Baseline and 3 months after the second-eye surgery
Uncorrected distance visual acuity, uncorrected intermediate visual acuity, uncorrected near visual acuity, corrected distance visual acuity, distance-corrected intermediate visual acuity, and distance-corrected near visual acuity will be measured using logarithm of the minimum angle of resolution units. Testing distances will be 4 m for distance, 60 cm for intermediate, and 40 cm for near vision.
Baseline and 3 months after the second-eye surgery
Whole-Eye Aberrations
Délai: Baseline and 3 months after the second-eye surgery
Whole-eye optical aberrations measured using the same wavefront aberrometry device and standardized testing parameters for all participants.
Baseline and 3 months after the second-eye surgery
Visual Disturbance Questionnaire Score
Délai: Baseline and 3 months after the second-eye surgery
Participant-reported frequency or severity of glare, halos, starbursts, and other visual disturbances assessed using a standardized visual quality questionnaire.
Baseline and 3 months after the second-eye surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Jin Yang

Les enquêteurs

  • Chercheur principal: Jin Yang, Fudan University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 août 2026

Achèvement primaire (Estimé)

30 août 2031

Achèvement de l'étude (Estimé)

31 août 2031

Dates d'inscription aux études

Première soumission

5 août 2026

Première soumission répondant aux critères de contrôle qualité

5 août 2026

Première publication (Réel)

10 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • TriIOL-2026

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner